Author Correction: Real-world ANASTASE study of atezolizumab+nab-paclitaxel as first-line treatment of PD-L1-positive metastatic triple-negative breast cancer

被引：0
|
作者：
Alessandra Fabi
Luisa Carbognin
Andrea Botticelli
Ida Paris
Paola Fuso
Maria Cristina Savastano
Nicla La Verde
Carla Strina
Rebecca Pedersini
Stefania Guarino
Giuseppe Curigliano
Carmen Criscitiello
Mimma Raffaele
Alessandra Beano
Antonio Franco
Maria Rosaria Valerio
Francesco Verderame
Andrea Fontana
Eva Regina Haspinger
Alessia Caldara
Alba Di Leone
Giampaolo Tortora
Diana Giannarelli
Giovanni Scambia
机构：
[1] Fondazione Policlinico Universitario A. Gemelli IRCCS,Precision Medicine Unit in Senology
[2] Fondazione Policlinico Universitario A. Gemelli IRCCS,Division of Gynecology Oncology, Department of Woman and Child Health and Public Health
[3] University of Rome,Medical Oncology Unit, La Sapienza
[4] Medical Oncology Unit,Department of Oncology and Hemato
[5] A.O.U. San Giovanni di Dio e Ruggi D’Aragona,Oncology
[6] Medical Oncology Unit,Department of Medical Oncology1
[7] ASST Fatebenefratelli Sacco PO Luigi Sacco - Polo Universitario,Breast Unit, Department of Women, Children and Public Health Sciences
[8] Medical Oncology Unit Azienda Socio-Sanitaria Territoriale Cremona,Medical Oncology, Department of Translational Medicine and Surgery
[9] Medical Oncology Unit ASST Spedali Civili,Epidemiology and Biostatistics Facility
[10] Medical Oncology Unit Santa Maria della Misericordia Hospital,undefined
[11] University of Milan,undefined
[12] Division of Early Drug Development,undefined
[13] European Institute of Oncology,undefined
[14] IRCCS,undefined
[15] Presidio Cassia Sant’andrea,undefined
[16] Dipartimento Oncologico,undefined
[17] Asl Roma1,undefined
[18] Città della Salute e della Scienza Hospital,undefined
[19] Fondazione Policlinico Universitario Agostino Gemelli IRCCS,undefined
[20] Medical Oncology,undefined
[21] Policlinico Universitario P. Giaccone,undefined
[22] Medical Oncology,undefined
[23] AO Riuniti Villa Sofia,undefined
[24] Cervello,undefined
[25] Medical Oncology Unit 2,undefined
[26] Azienda Ospedaliero-Universitaria Pisana,undefined
[27] Azienda Sanitaria dell’Alto Adige – Ospedale di Merano,undefined
[28] Santa Chiara Hospital,undefined
[29] Medical Oncology,undefined
[30] Fondazione Policlinico Universitario A. Gemelli IRCCS,undefined
[31] Università Cattolica del Sacro Cuore,undefined
[32] Fondazione Policlinico Universitario A. Gemelli IRCCS,undefined
[33] Università Cattolica del Sacro Cuore,undefined
来源：
npj Breast Cancer | / 10卷
关键词：
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 50 条
  • [21] ATRACTIB: A phase II trial of first-line (1L) atezolizumab (A) in combination with paclitaxel (P) and bevacizumab (B) in metastatic triple-negative breast cancer (mTNBC)
    Cortes Salgado, A.
    Perez Garcia, J. M.
    Cortez Castedo, S. P.
    Gion Cortes, M.
    Morales Murillo, S.
    Blancas Lopez-Barajas, I.
    Blanch, S.
    Calvo Plaza, I.
    Diaz Fernandez, N.
    Marme, F.
    Martinez Bueno, A.
    Taberner Bonastre, M. T.
    De laurentiis, M.
    Ruiz Borrego, M.
    Schmid, P.
    Guarneri, V.
    Gligorov, J.
    Sampayo-Cordero, M.
    Llombart Cussac, A.
    Cortes, J.
    ANNALS OF ONCOLOGY, 2022, 33 : S221 - S221
  • [22] A phase Ill randomized trial of atezolizumab in combination with nab-paclitaxel as first line therapy for patients with metastatic triple-negative breast cancer (mTNBC)
    Emens, L.
    Adams, S.
    Loi, S.
    Schmid, P.
    Schneeweiss, A.
    Rugo, H.
    Chui, S.
    Winer, E.
    CANCER RESEARCH, 2016, 76
  • [23] PD-L1 Immunohistochemistry Assay Comparison in Atezolizumab Plus nab-Paclitaxel-Treated Advanced Triple-Negative Breast Cancer
    Rugo, Hope S.
    Loi, Sherene
    Adams, Sylvia
    Schmid, Peter
    Schneeweiss, Andreas
    Barrios, Carlos H.
    Iwata, Hiroji
    Dieras, Veronique
    Winer, Eric P.
    Kockx, Mark M.
    Peeters, Dieter
    Chui, Stephen Y.
    Lin, Jennifer C.
    Duc, Anh Nguyen
    Viale, Giuseppe
    Molinero, Luciana
    Emens, Leisha A.
    JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2021, 113 (12): : 1733 - 1743
  • [24] First-line atezolizumab plus nab-paclitaxel for unresectable, locally advanced, or metastatic triple-negative breast cancer: IMpassion130 final overall survival analysis
    Emens, L. A.
    Adams, S.
    Barrios, C. H.
    Dieras, V
    Iwata, H.
    Loi, S.
    Rugo, H. S.
    Schneeweiss, A.
    Winer, E. P.
    Patel, S.
    Henschel, V
    Swat, A.
    Kaul, M.
    Molinero, L.
    Patel, S.
    Chui, S. Y.
    Schmid, P.
    ANNALS OF ONCOLOGY, 2021, 32 (08) : 983 - 993
  • [25] Immune Landscape in PD-L1-positive and TROP2-positive Triple-Negative Breast Cancer
    Gyorffy, Balazs
    Santarpia, Libero
    CANCER RESEARCH, 2024, 84 (09)
  • [26] Phase II COLET study: Atezolizumab (A) plus cobimetinib (C) plus paclitaxel (P)/nab-paclitaxel (nP) as first-line (1L) treatment (tx) for patients (pts) with locally advanced or metastatic triple-negative breast cancer (mTNBC).
    Brufsky, Adam
    Kim, Sung-Bae
    Zvirbule, Zanete
    Dirix, Luc Yves
    Eniu, Alexandru E.
    Carabantes, Francisco
    Izarzugaza, Yann
    Mebis, Jeroen
    Sohn, Joohyuk
    Wongchenko, Matthew
    Chohan, Saibah
    Amin, Reena
    McNally, V. A.
    Miles, David
    Loi, Sherene
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [27] The cost-effectiveness of atezolizumab in first-line for metastatic triple negative breast cancer is heavily linked to PD-L1 level
    Giuliani, Jacopo
    Mantoan, Beatrice
    Bonetti, Andrea
    JOURNAL OF ONCOLOGY PHARMACY PRACTICE, 2021, 27 (05) : 1245 - 1247
  • [28] First-Line Ipatasertib, Atezolizumab, and Taxane Triplet for Metastatic Triple-Negative Breast Cancer: Clinical and Biomarker Results
    Schmid, Peter
    Turner, Nicholas C.
    Barrios, Carlos H.
    Isakoff, Steven J.
    Kim, Sung-Bae
    Sablin, Marie-Paule
    Saji, Shigehira
    Savas, Peter
    Vidal, Gregory A.
    Oliveira, Mafalda
    O'Shaughnessy, Joyce
    Italiano, Antoine
    Espinosa, Enrique
    Boni, Valentina
    White, Shane
    Rojas, Beatriz
    Freitas-Junior, Ruffo
    Chae, Yeesoo
    Bondarenko, Igor
    Lee, Jieun
    Mattos, Cesar Torres
    Rodriguez, Jorge Luis Martinez
    Lam, Lisa H.
    Jones, Surai
    Reilly, Sarah-Jayne
    Huang, Xiayu
    Shah, Kalpit
    Dent, Rebecca
    CLINICAL CANCER RESEARCH, 2024, 30 (04) : 767 - 778
  • [29] Phase 2 study of pembrolizumab as first-line therapy for PD-L1-positive metastatic triple-negative breast cancer (mTNBC): Preliminary data from KEYNOTE-086 cohort B.
    Adams, Sylvia
    Loi, Sherene
    Toppmeyer, Deborah
    Cescon, David W.
    De laurentiis, Michele
    Nanda, Rita
    Winer, Eric P.
    Mukai, Hirofumi
    Tamura, Kenji
    Armstrong, Anne
    Liu, Minetta C.
    Iwata, Hiroji
    Ryvo, Larisa
    Wimberger, Pauline
    Card, Deborah
    Ding, Yu
    Karantza, Vassiliki
    Schmid, Peter
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [30] Safety and efficacy of Atezolizumab in combination with nab-Paclitaxel in patients with PD-L1 positive metastatic or locally advanced triple-negative breast cancer: A pan-UK cancer centre experience
    Waterhouse, Jasmin V.
    Holdich, Alexandra
    Mina, Florentia
    Obeid, Mariam
    Joshi, Kroopa
    Barrett, Sophie
    Rajakumar, Lavarniya
    McCormick, Gemma
    Seymour, Sally
    Koliou, Panagiotis
    Sylva, Rushan
    Ayodele, Olubukola
    Gautam, Ashram
    Smith, Jenny
    McKeon, Jenny
    Strawson-Smith, Thomas
    Douglas, Rosalie
    Borley, Annabel
    Konstantis, Apostolos
    McGrath, Sophie
    CANCER RESEARCH, 2024, 84 (09)
12345